Researchers at Dana-Farber and the Baylor College of Medicine have shown that Tensha's bromodomain inhibitors could prevent sperm production and be developed as a male contraceptive. The biotech, which is focused on developing the molecules for cancer, has exclusive rights to the findings and is interested in pursuing bromodomain inhibitors in the indication.